Exelixis, Inc. (NASDAQ:EXEL) Analyst Estimates

Exelixis, Inc. (NASDAQ:EXEL) Analyst Estimates

Exelixis, Inc. (NASDAQ:EXEL) Analyst Estimates

Exelixis, Inc. (NASDAQ:EXEL) stock is presently standing at about $21.85 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 4 analysts covering the company is $26.00, which suggests the stock could still rise over 16 percent. The highest analyst price target is $26.00, which implies a rally of 81 percent. And a quick view of analyst notes show that 3 are rating the stock a buy while 3 rate EXEL a strong buy. There are 0 equity research firms advocating a Hold and 0 consider it Sell.

Stifel analysts provided their view on Exelixis, Inc. (NASDAQ:EXEL) recently. The rating firm issued a Hold rating to this company in a research note released on Feb 28, 2017. Deutsche Bank analysts disclosed their opinion on Exelixis, Inc. (NASDAQ:EXEL) recently. The rating firm gave a Buy rating to this stock in a research note published on Nov 03, 2016. According to a research note disclosed on Oct 10, 2016, analysts at Piper Jaffray have upped their rating on these shares from Neutral to Overweight.

Exelixis, Inc. (NASDAQ:EXEL) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its Director MARCHESI VINCENT T sold 40,000 company shares for 879200, in a transaction on 2017-03-10. Following the transaction, the Director is left with a stake of 120,070 shares, currently valued at $2623530. Meanwhile, President and CEO MORRISSEY MICHAEL sold 200,000 shares worth $4544000, through a transaction dated 2017-03-06. Following the completion of the transaction, the insider is left with a stake of 249,523 shares, amounting $5452077.55. EXEL EVP and General Counsel Hessekiel Jeffrey also sold 100,000 shares, at a stock price of $23.04. This transaction occurred on 2017-03-03 totals $2304000. After this transaction, the insider’s stake stands at 246,617 shares, with a market value of $5388581.

Executives hold 1.69 percent of the stock. Dr. George A. Scangos,PhD is one of the biggest insider owners in Exelixis, Inc. (NASDAQ:EXEL), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 1,463,648 shares which have current market value of around $31980708.8.Dr. Stelios Papadopoulos,PhD is another major inside shareholder in the company. The insider owns 1,228,471 shares as of 0.42%, currently worth $26842091.35. Dr. Lance Willsey,M.D. is ranked as third insider holder of the stock. This insider holds 568,273 shares with a market value around $12416765.05 as of recent close.

Exelixis, Inc. (NASDAQ:EXEL) Earnings Outlook

In Exelixis, Inc. (NASDAQ:EXEL)’s latest quarter, EPS moved to $0.12 from $-0.04 in preceding quarter and revenues reached at $77.58M compared to $62.19M. Analysts had expected Exelixis, Inc. (NASDAQ:EXEL) to post net income of about $-0.01 per share on $66.50M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.02 to $0.01. That is compared with the $-0.27 in EPS it reported during the same period a year ago.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.